Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies
Modern Rheumatology · 02.03.2023 · 33 (2) · 279-291
DOI: 10.1093/mr/roac036 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Modern Rheumatology, online erschienen am 21.04.2022. Verfasst von Tomonori Ishii und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To assess the safety and pharmacokinetics (PK) of single-dose subcutaneous (SC) sarilumab or tocilizumab SC ± methotrexate (MTX) and to assess the pharmacodynamics (PD) of sarilumab SC or tocilizumab SC monotherapy in Japanese rheumatoid arthritis (RA) patients.
Methods
TDU13402 was a randomized, double-blind, placebo-controlled, single-ascending dose Phase 1 study (NCT01850680). Twenty-four patients (6 per treatment group) received sarilumab 50, 100, or 200 mg plus MTX or placebo (2 per cohort) on Day (D) 1; PK and safety were assessed through D57. PDY14191 was a randomized, open-label, single-dose study (NCT02404558). Thirty patients (15 per arm) received sarilumab 150 mg or tocilizumab 162 mg on D1; PK, PD, and safety were assessed through D43.
Results
TDU13402: mean serum sarilumab exposure increased in a greater than dose proportional manner from 50 to 200 mg dose with no clinically meaningful increase in treatment-emergent adverse events (TEAEs). PDY14191: PK profiles of single-dose sarilumab 150 mg or tocilizumab 162 mg were similar; some numerical differences in PD profiles and TEAEs were observed. Neutrophil count decrease/neutropenia was the most frequently reported TEAE with sarilumab treatment in both studies.
Conclusions
PK, PD, and safety profiles of single-dose sarilumab SC with/without MTX were consistent with results anticipated in Japanese patients with RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
- Kaiyama Central Hospital, Sendai, Miyagi, Japan.
- Soushi-kai Munakata Yasuhiko Clinic, Sendai, Miyagi, Japan.
- Research and Development, Sanofi K.K., Shinjuku, Tokyo, Japan.
- Global Medical Affairs, Sanofi, Cambridge, MA, USA.
- Translational Medicine and Early Development, Sanofi, Bridgewater, NJ, USA.
Zitieren
APA
Ishii, T., Sato, Y., Munakata, Y., Kajiwara, M., Takahashi, Y., van Hoogstraten, H., Xu, C., Kato, N., & Takahashi, T. (2023). Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies. Modern Rheumatology, 33(2), 279-291. https://doi.org/10.1093/mr/roac036
Vancouver
Ishii T, Sato Y, Munakata Y, Kajiwara M, Takahashi Y, van Hoogstraten H, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies. Modern Rheumatology. 2023;33(2):279-291. doi:10.1093/mr/roac036
BibTeX
@article{Ishii2023,
author = {Ishii, Tomonori and Sato, Yukio and Munakata, Yasuhiko and Kajiwara, Miyuki and Takahashi, Yoshinori and van Hoogstraten, Hubert and Xu, Christine and Kato, Naoto and Takahashi, Toshiya},
title = {Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies},
journal = {Modern Rheumatology},
year = {2023},
volume = {33},
number = {2},
pages = {279--291},
doi = {10.1093/mr/roac036}
}
EUVIMED